HLS Therapeutics Inc.
HLTRF
$2.72
$0.082.96%
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 14.06% | -15.34% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 14.06% | -15.34% | |||
| Cost of Revenue | 8.76% | -2.03% | |||
| Gross Profit | 16.62% | -20.55% | |||
| SG&A Expenses | 7.34% | 2.59% | |||
| Depreciation & Amortization | -0.18% | 1.34% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.97% | 0.81% | |||
| Operating Income | 47.81% | -1,034.60% | |||
| Income Before Tax | 56.12% | -15.79% | |||
| Income Tax Expenses | 550.00% | 100.31% | |||
| Earnings from Continuing Operations | 55.59% | -72.06% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 55.59% | -72.06% | |||
| EBIT | 47.81% | -1,034.60% | |||
| EBITDA | 31.59% | -35.91% | |||
| EPS Basic | 55.59% | -83.50% | |||
| Normalized Basic EPS | 56.21% | -23.72% | |||
| EPS Diluted | 55.59% | -83.50% | |||
| Normalized Diluted EPS | 56.21% | -23.72% | |||
| Average Basic Shares Outstanding | 0.00% | -6.30% | |||
| Average Diluted Shares Outstanding | 0.00% | -6.30% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||